Atypical hemolytic uremic syndrome
DOI:
https://doi.org/10.32818/reccmi.a5n3a2Keywords:
uremic syndrome, eculizumab, plasmapheresis, thrombotic microangiopathy.Abstract
Atypical Hemolytic Uremic Syndrome is a very rare, rapidly progressive, high morbidity and mortality illness, especially when it is not recognized and treated. This subtype is classified in primary and secondary. It is characterized by the triad of microangiopathic haemolytic anemia, thrombocytopenia, and renal failure; however, this clinical case occurring mainly with extrarenal clinical manifestations, especially of neurological origin and an uncontrolled pregnancy recent history; other differential diagnoses were excluded. Furthermore were started medical treatment with plasmapheresis and eculi- zumab, achieving clinical radiological, and blood test improvement.
Downloads
Metrics
References
Córdoba JP, Contreras KM, Larrarte C, Espitaleta Z, González LE, Ibarra M, et al. Síndrome hemolítico urémico atípico, revisión de la literatura y documento de consenso. Enfoque diagnóstico y tratamiento. Rev. Colomb. Nefrol. 2015; 2(1): 19-0. Disponible en: https://revistanefrologia.org/index.php/rcn/article/view/199.
Camargo Assis F, Ortiz Ruiz G, Garay Fernández M, Córdoba JP, Yepes D, González M, et al. Microangiopatías trombóticas en la unidad de cuidados intensivos. Acta Colombiana de Cuidado Intensivo. 2017; 17(2): 117-128. doi: https://doi.org/10.1016/j.acci.2017.02.003.
Huerta A, Arjona E, Portoles J, Lopez-Sanchez P, Rabasco C, Espinosa M, et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int. 2018; 93(2): 450-459. doi: https://doi.org/10.1016/j.kint.2017.06.022.
Fakhouri F, Fila M, Provôt F, Delmas Y, Barbet C, Châtelet V, et al. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. Clin J Am Soc Nephrol. 2017; 12(1): 50-59. doi: https://doi.org/10.2215/CJN.06440616.
Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia. 2015;35(5):421-47. doi: https://doi.org/10.1016/j.nefro.2015.07.005.
Müller-Calleja N, Ritter S, Hollerbach A, Falter T, Lackner KJ, Ruf W. Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies. Blood Adv. 2018; 2(9): 979-986. doi: https://doi.org/10.1182/bloodadvances.2018017095.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Andrés David Villa-García, Camilo Andrés García-Prada, Mario Alejandro Villabón-González, Sandra Marcela Figueroa-Cárdenas, Fernando Iván Meza-Morón
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
